Twist launches new biotech firm

By The Science Advisory Board staff writers

November 15, 2021 -- Twist Bioscience has launched a new biotechnology firm, Revelar Biotherapeutics, to develop and market an antibody discovered by Twist that neutralizes SARS-CoV-2.

Twist expects Revelar to begin clinical studies of the antibody in 2022. It will also license up to five additional antibodies developed by Twist over the next four years. Twist may receive milestone payments from Revelar of more than $100 million for development, regulatory, and commercial milestones, it said.

Copyright © 2021

MemberID or email address:  

Forgot your password?